Stoke Therapeutics, Inc. (STOK) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Stoke Therapeutics, Inc. (STOK) closed at USD 23.26 on 2026-10-14, a change of -26.5 % over the past year, with a market capitalization of USD 1.59B.

Stoke Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Stoke Therapeutics, Inc. key figures

Previous close

USD 23.26 (2026-10-14)

1-year change

-26.5 %

Market cap

USD 1.59B

Enterprise value

USD 1.3B

P/E ratio (trailing)

-6.65

P/E ratio (forward)

-6.98

EPS (trailing)

-3.70

EPS (forward)

-3.53

PEG ratio

n/a

Price to book

4.44

Revenue growth

-32.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.49

Employees

170

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Stoke Therapeutics, Inc. and compare it with other stocks.